• Althea Technologies Inc., of San Diego, named Rick Hancock president and CEO, Chris Duffy senior vice president of operations and E.J. Brandreth senior vice president of quality and regulatory.

• Axelar AB, of Stockholm, Sweden, named Harald Janson CEO.

• BIND Biosciences Inc., of Cambridge, Mass., named Daniel S. Lynch chairman of its board.

• BioRestorative Therapies Inc., of Jupiter, Fla., named Wayne A. Marasco chairman of its scientific advisory board.

• Cardiome Pharma Corp., of Vancouver, British Columbia, appointed Jennifer Archibald chief financial officer.

• Cardium Therapeutics Inc., of San Diego, appointed the following members to its new medical advisory board: Rudolph C. Anderson Jr., Jay S. Berenter, James Blaine, Anthony Cannizzaro, John D. Halebian, Howard M. Kimmel, Lawrence A. Lavery, Eric J. Lullove, William D. McDonald, Jeffrey A. Ross, Arthur J. Tallis, David A. Yeager and Stephanie C. S. Wu.

• EffRx Pharmaceuticals SA, of Freienbach, Switzerland, appointed Lorenzo Bosisio vice president, head of business development and marketing.

• Igenica Inc., of Burlingame, Calif., appointed Mary Haak Frendscho CEO.

• Immunovaccine Inc., of Halifax, Nova Scotia, added Scott Halperin to its scientific advisory board.

• InVivo Therapeutics Holdings Corp., of Cambridge, Mass., named Brian Hess interim chief science officer.

• Medigene AG, of Martinsried, Germany, added Peter Llewellyn-Davies to its executive management board.

• Lightlake Therapeutics Inc., of London, appointed David Kessler strategic advisor.

• Omeros Corp., of Seattle, added Arnold C. Hanish to its board and appointed him chairman of the audit committee.

• Oncolytics Biotech Inc., of Calgary, Alberta, named Alan J. Tuchman chief medical officer and senior vice president, clinical and medical development.

• Osiris Therapeutics Inc., of Columbia, Md., added Hans Klingemann to its board, and appointed him to the audit, compensation and nominating committees.

• PTC Therapeutics Inc., of South Plainfield, N.J., added Jerome B. Zeldis to its board.

• Savient Pharmaceuticals Inc., of East Brunswick, N.J., named John P. Hamill senior vice president and chief financial officer.

• Shire plc, of Dublin, Ireland, appointed Frederic Chereau senior vice president and franchise lead, angiodema; he will be based in Lexington, Mass.

• SpringLeaf Therapeutics Inc., of Boston, appointed Pieter Muntendam president and CEO.

• Ventrus Biosciences Inc., of New York, appointed JP Benya vice president, commercial operations and business development.

• Vertex Pharmaceuticals Inc., of Cambridge, Mass, added Yuchun Lee to its board.